PubRank

Elizabeth A Musgrove

Author PubWeight™ 68.61‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012 8.31
2 Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol 2013 2.26
3 Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003 2.14
4 PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2010 1.89
5 Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 2005 1.73
6 Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 2004 1.73
7 Cell cycle control in breast cancer cells. J Cell Biochem 2006 1.68
8 The E3 ubiquitin ligase EDD regulates S-phase and G(2)/M DNA damage checkpoints. Cell Cycle 2007 1.36
9 Dysregulation of Hedgehog, Wnt and Notch signalling pathways in breast cancer. Histol Histopathol 2009 1.32
10 Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein. J Biol Chem 2005 1.32
11 Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol Biomarkers Prev 2010 1.31
12 Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 2008 1.28
13 Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer. Gastroenterology 2009 1.27
14 Distinct and redundant functions of cyclin E1 and cyclin E2 in development and cancer. Cell Div 2010 1.27
15 Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup. PLoS One 2009 1.25
16 Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer. Cancer Res 2011 1.25
17 c-Myc overexpression and endocrine resistance in breast cancer. J Steroid Biochem Mol Biol 2006 1.22
18 Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 2002 1.21
19 Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene 2005 1.20
20 Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc. Mol Cell Biol 2009 1.16
21 Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007 1.14
22 Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2004 1.13
23 Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle 2013 1.09
24 Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. PLoS One 2011 1.07
25 Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002 1.07
26 Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells. Cell Cycle 2013 1.03
27 Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Mol Cancer Ther 2012 1.01
28 Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res 2001 1.00
29 Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics. Crit Rev Oncog 2012 1.00
30 Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX. Breast Cancer Res 2012 0.98
31 p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 2003 0.98
32 The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini. Cancer Res 2008 0.93
33 CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 2009 0.92
34 Live or let die: oestrogen regulation of survival signalling in endocrine response. Breast Cancer Res 2007 0.92
35 High Notch1 protein expression is an early event in breast cancer development and is associated with the HER-2 molecular subtype. Histopathology 2010 0.92
36 Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. FEBS J 2013 0.91
37 The NSAID sulindac is chemopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut 2010 0.89
38 Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer. PLoS One 2012 0.89
39 Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor. Cancer Res 2007 0.89
40 Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 2003 0.88
41 BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. Mol Cancer Ther 2013 0.88
42 Clinical and pathologic features of familial pancreatic cancer. Cancer 2014 0.86
43 Cortactin modulates RhoA activation and expression of Cip/Kip cyclin-dependent kinase inhibitors to promote cell cycle progression in 11q13-amplified head and neck squamous cell carcinoma cells. Mol Cell Biol 2010 0.85
44 The cyclin-dependent kinase inhibitor p27 (Kip1) regulates both DNA synthesis and apoptosis in mammary epithelium but is not required for its functional development during pregnancy. Mol Endocrinol 2003 0.85
45 Sulindac activates NF-κB signaling in colon cancer cells. Cell Commun Signal 2013 0.85
46 Hormonal regulation of the Grb14 signal modulator and its role in cell cycle progression of MCF-7 human breast cancer cells. J Cell Physiol 2005 0.84
47 Cyclin E and prognosis in patients with breast cancer. N Engl J Med 2002 0.84
48 The PDZ-binding motif of MCC is phosphorylated at position -1 and controls lamellipodia formation in colon epithelial cells. Biochim Biophys Acta 2012 0.82
49 The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome. Breast Cancer Res 2008 0.82
50 Mutated in colorectal cancer protein modulates the NFκB pathway. Anticancer Res 2012 0.82
51 RB in breast cancer: differential effects in estrogen receptor-positive and estrogen receptor-negative disease. Cell Cycle 2010 0.82
52 LMO4 expression in squamous cell carcinoma of the anterior tongue. Histopathology 2011 0.81
53 p14ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 2005 0.81
54 Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. Int J Cancer 2010 0.81
55 Cyclin E expression and outcome in pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006 0.80
56 The "Mutated in Colorectal Cancer" Protein Is a Novel Target of the UV-Induced DNA Damage Checkpoint. Genes Cancer 2010 0.79
57 Retinoid signaling in pancreatic cancer, injury and regeneration. PLoS One 2011 0.79
58 Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 2017 0.75